| Similar Articles |
|---|
 |
The Motley Fool
November 17, 2009
Dave Mock |
A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.   |
The Motley Fool
October 26, 2009
Dave Mock |
A Big Upgrade for Electro-Optical Sciences This bullish call comes from more than just one analyst. The Food and Drug Administration has put Electro-Optical Sciences' melanoma detection device on the fast track. |
The Motley Fool
January 20, 2010
Dave Mock |
A Big Upgrade for Smart Balance A total of 210 Motley Fool analysts have given their opinion on the food-products marketer, with many of them offering analysis and commentary explaining the recent optimism, and raising the stock to a four-star rating. |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. |
The Motley Fool
January 27, 2011
Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
The Motley Fool
February 25, 2010
Dave Mock |
A Big Upgrade for Xilinx After more than a year at a mediocre three-star ranking, enough top-performing Motley Fool CAPS members turned bullish on Xilinx recently to take it to the four-star level. |
The Motley Fool
March 1, 2010
Dave Mock |
A Big Upgrade for Allstate After more than a year at a three-star rank, enough top-performing Motley Fool CAPS members have turned bullish on Allstate recently to upgrade it to a more formidable four stars. |
The Motley Fool
October 9, 2009
Dave Mock |
A Big Upgrade for Micron Technology After being rated at no better than a two-star rank for the past several months, enough top-performing Motley Fool analysts have turned bullish on processor maker Micron Technology in the past month to upgrade it to a more formidable three stars. |
The Motley Fool
February 23, 2010
Dave Mock |
A Big Upgrade for Art Technology Group After being stuck for more than a year at no better than a three-star rank, enough top-performing CAPS members have turned bullish on e-commerce software provider Art Technology Group to upgrade it to a more formidable four stars. |
The Motley Fool
November 2, 2009
Dave Mock |
A Big Upgrade for Hudson City Bancorp This bullish call comes from more than just one analyst. |
The Motley Fool
January 27, 2010
Dave Mock |
A Big Upgrade for Coinstar It had been stuck at a two-star rating for years, but enough top-performing Motley Fool CAPS members have turned bullish on Coinstar recently to upgrade it to a more formidable three stars. |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. |
The Motley Fool
November 24, 2009
Dave Mock |
A Big Upgrade for Time Warner After lumbering along at a lowly two-star rank for most of the past year, enough top-performing Motley Fool analysts have turned bullish on Time Warner recently to upgrade it to three stars. |
The Motley Fool
January 29, 2010
Dave Mock |
A Big Upgrade for MetLife This bullish call comes from more than just one analyst. |
The Motley Fool
August 26, 2009
Dave Mock |
A Big Upgrade for Sonus Networks Sonus Networks has seen more and more top-performing Motley Fool members come to the bullish side of the stock. |
The Motley Fool
October 7, 2009
Dave Mock |
A Big Upgrade for Tenet Healthcare This bullish call comes from more than just one analyst. |
The Motley Fool
January 13, 2010
Dave Mock |
A Big Upgrade for The Buckle This bullish call comes from more than just one analyst. |
The Motley Fool
October 13, 2009
Dave Mock |
A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst. |
The Motley Fool
October 21, 2009
Dave Mock |
A Big Upgrade for Smith & Wesson This bullish call on Smith & Wesson comes from many Motley Fool analysts after it beat expectations. |
The Motley Fool
March 8, 2010
Dave Mock |
A Big Upgrade for National Semiconductor After being locked for more than six months at a less-than-impressive two-star rank, enough top-performing Motley Fool CAPS members have turned bullish on National Semiconductor recently to upgrade it to a more palatable three stars. |
The Motley Fool
October 21, 2009
Brian Orelli |
Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession. |
The Motley Fool
July 22, 2009
Brian Orelli |
Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences. |
The Motley Fool
January 28, 2009
Brian Orelli |
Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter. |
The Motley Fool
October 17, 2008
Brian Orelli |
Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results. |
The Motley Fool
December 28, 2009
Dave Mock |
A Big Upgrade for Gulf Resources Enough top-performing Motley Fool CAPS members have turned bullish on the chemicals maker recently to upgrade it to four stars. |
The Motley Fool
July 21, 2006
Brian Lawler |
Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet. |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back. |
The Motley Fool
July 18, 2008
Brian Lawler |
Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future. |
The Motley Fool
November 23, 2009
Dave Mock |
A Big Upgrade for Toyota Motor This bullish call comes from more than just one analyst. |
The Motley Fool
October 1, 2009
Dave Mock |
A Big Upgrade for Lockheed Martin Lockheed Martin gets a big upgrade from many top-performing Motley Fool analysts. |
The Motley Fool
April 22, 2009
Brian Orelli |
Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy. |
The Motley Fool
July 27, 2011
Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
The Motley Fool
July 21, 2010
Brian Orelli |
15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth. |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note. |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
February 18, 2010
Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
The Motley Fool
August 26, 2008
Dave Mock |
A Big Upgrade for Southern This bullish call for electrical utility Southern comes from more than just one analyst. |
The Motley Fool
November 12, 2009
Dave Mock |
A Big Upgrade for B&G Foods Enough Motley Fool analysts have become bullish on B&G Foods to elevate the stock to five-star status. |
The Motley Fool
September 20, 2011
Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
July 23, 2007
Brian Lawler |
Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note. |
The Motley Fool
December 16, 2008
Dave Mock |
A Big Upgrade for AIG While it may be hard to believe, more top-performing CAPS members are turning bullish on American International Group these days, exhibiting optimism for the future. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
February 4, 2010
Brian Orelli |
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? |
The Motley Fool
July 19, 2010
Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
The Motley Fool
March 16, 2007
Brian Lawler |
Select Comfort vs. Gilead Sciences: Gilead Sciences In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Investors, here is why Gilead should go all the way. |
BusinessWeek
September 18, 2006
Gene G. Marcial |
Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted. |
The Motley Fool
May 24, 2011
Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
